Gilead keeps push­ing trove of Trodelvy da­ta as it seeks to be­come new stan­dard of care in TNBC

Gilead is con­tin­u­ing to churn out re­sults for its new­ly ap­proved drug Trodelvy, and #ES­MO21 is the lat­est stop on the da­ta train.

The bio­phar­ma put out new qual­i­ty of life da­ta in sec­ond-line pa­tients with metasta­t­ic triple-neg­a­tive breast can­cer, say­ing that a sub-analy­sis from their Phase III study showed sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ments in health-re­lat­ed qual­i­ty of life over stan­dard of care.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.